Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02008227 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,225
- Enrollment target
NCT02008227 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,225 participants.
The verdict
NCT02008227, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,225 participants
- Enrollment target
Study Summary
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \[anti-PD-L1\] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
Interventions
- DRUG Docetaxel
- DRUG Atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,225 participants |
| Start Date | 2014-03-11 |
| Est. Completion | 2019-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02008227
The ClinicalTrials.gov registry entry for NCT02008227 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT02008227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02008227 about?
NCT02008227 is a clinical study titled "A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy". This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \[anti-PD-L1\] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure...
What is the current status of trial NCT02008227?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,225 participants. The study started on 2014-03-11. Estimated completion is 2019-01-09.
What interventions are being tested in trial NCT02008227?
The interventions under investigation include: Docetaxel (DRUG), Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT02008227?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.